The study met its primary endpoint in enhancing event-free survival over 12 months when compared to historical control groups ...

Maxim analyst Jason McCarthy raised the firm’s price target on OS Therapies (OSTX) to $15 from $8 and keeps a Buy rating on the shares. The firm cites the company’s positive Phase 2b top-line data for ...

OS Therapies (OSTX) up 65% in premarket trading after positive phase 2b data on OST-HER2 for lung metastatic osteosarcoma ...

Financially risky OS Therapies has potential with mid-stage immunotherapy for osteosarcoma, but faces funding challenges and ...

The therapy, dubbed OST-HER2, uses a HER2-bioengineered form of the bacteria Listeria monocytogenes to trigger an immune ...

OS Therapies (NYSE:OSTX – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a research note issued on Wednesday,Benzinga reports. They currently have a ...

OS Therapies (OSTX) announced data from a Phase 2b clinical trial of OST-HER2 – the company’s HER2-targeted immunotherapy candidate in the rare ...

In recent trading, OS Therapies Inc (OSTX) stock price has shown some volatility, fluctuating -11.02% over the last five trades and -2.24% over the past 30 trades. This represents a notable shift from ...

With positive data in hand from its phase IIb trial testing immunotherapy candidate OST-HER2 in osteosarcoma, OS Therapies ...

OS Therapies shares surged Wednesday after the biotech company reported positive data from a clinical trial for its cancer treatment OST-HER2. Shares of the N.Y., clinical-stage biotechnology company ...

OS Therapies shares Phase 2b trial results showing OST-HER2 improves survival rates in rare metastatic osteosarcoma, surpassing historical controls.

OS Therapies Inc (NYSE American:OSTX), a biopharmaceutical company specializing in ADC and immunotherapy with a current market capitalization of $98.76 million, has completed a second private ...